Estás usando un navegador no soportado
Usar Internet Explorer está desaconsejado por problemas de seguridad. Para ver correctamente esta web, por favor use cualquier navegador moderno: Chrome, Firefox, Edge, Safari u otro de su elección.
En este apartado encontrará una actualización mensual de Trastornos del Movimiento
FILTRAR POR:
Por tema
6262 ARTÍCULOS , VIENDO DEL 2536 AL 2550
Glutamate Receptors and C-ABL Inhibitors: A New Therapeutic Approach for Parkinson's Disease
Shejul PP, Doshi GM.
Cent Nerv Syst Agents Med Chem. 2024;24(1):22-44. doi: 10.2174/0118715249268627231206115942.
Garabedian M, Keltz A, Lerner MZ, Brackett A, Leydon C.
J Voice. 2024 Oct 21:S0892-1997(24)00326-6. doi: 10.1016/j.jvoice.2024.09.034. Online ahead of print.
The Olfactory Trail of Neurodegenerative Diseases
Franco R, Garrigós C, Lillo J.
Cells. 2024 Apr 2;13(7):615. doi: 10.3390/cells13070615.
Artificial intelligence in Parkinson's disease: Early detection and diagnostic advancements
Reddy A, Reddy RP, Roghani AK, Garcia RI, Khemka S, Pattoor V, Jacob M, Reddy PH, Sehar U.
Ageing Res Rev. 2024 Aug;99:102410. doi: 10.1016/j.arr.2024.102410. Epub 2024 Jul 5.
The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson's disease
Björklund A, Barker RA.
Brain. 2024 Jun 3;147(6):1937-1952. doi: 10.1093/brain/awae026.
Gold Nanoparticles in Parkinson's Disease Therapy: A Focus on Plant-Based Green Synthesis
Grancharova T, Simeonova S, Pilicheva B, Zagorchev P.
Cureus. 2024 Feb 22;16(2):e54671. doi: 10.7759/cureus.54671. eCollection 2024 Feb.
Calprotectin in Parkinsonian disease: Anticipation and dedication
Al-Kuraishy HM, Al-Gareeb AI, Zaidalkiani AT, Alexiou A, Papadakis M, Bahaa MM, Al-Faraga A, Batiha GE.
Ageing Res Rev. 2024 Jan;93:102143. doi: 10.1016/j.arr.2023.102143. Epub 2023 Nov 25.
PPAR agonists for the treatment of neuroinflammatory diseases
Titus C, Hoque MT, Bendayan R.
Trends Pharmacol Sci. 2024 Jan;45(1):9-23. doi: 10.1016/j.tips.2023.11.004. Epub 2023 Dec 7.
The Genetic Landscape of Sleep Disorders in Parkinson's Disease
Kalinderi K, Papaliagkas V, Fidani L.
Diagnostics (Basel). 2024 Jan 3;14(1):106. doi: 10.3390/diagnostics14010106.
The role of CD56(bright) NK cells in neurodegenerative disorders
Rodriguez-Mogeda C, van Ansenwoude CMJ, van der Molen L, Strijbis EMM, Mebius RE, de Vries HE.
J Neuroinflammation. 2024 Feb 13;21(1):48. doi: 10.1186/s12974-024-03040-8.
Long Non-Coding RNAs: New Insights in Neurodegenerative Diseases
Anilkumar AK, Vij P, Lopez S, Leslie SM, Doxtater K, Khan MM, Yallapu MM, Chauhan SC, Maestre GE, Tripathi MK.
Int J Mol Sci. 2024 Feb 14;25(4):2268. doi: 10.3390/ijms25042268.
Gold Nanoparticles in Neurological Diseases: A Review of Neuroprotection
Chiang MC, Yang YP, Nicol CJB, Wang CJ.
Int J Mol Sci. 2024 Feb 17;25(4):2360. doi: 10.3390/ijms25042360.
Wiersema AF, Rennenberg A, Smith G, Varderidou-Minasian S, Pasterkamp RJ.
Cell Mol Life Sci. 2024 Dec 3;81(1):479. doi: 10.1007/s00018-024-05522-7.
Commercial symptom monitoring devices in Parkinson's disease: benefits, limitations, and trends
Rodríguez-Martín D, Pérez-López C.
Front Neurol. 2024 Dec 23;15:1470928. doi: 10.3389/fneur.2024.1470928. eCollection 2024.
Animal Approaches to Studying Risk Factors for Parkinson's Disease: A Narrative Review
Silva RH, Lopes-Silva LB, Cunha DG, Becegato M, Ribeiro AM, Santos JR.
Brain Sci. 2024 Feb 2;14(2):156. doi: 10.3390/brainsci14020156.
Actualización mensual Regístrese para recibir los avisos de actualización
Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.